BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15958617)

  • 1. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
    Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
    Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
    Bergamaschi D; Gasco M; Hiller L; Sullivan A; Syed N; Trigiante G; Yulug I; Merlano M; Numico G; Comino A; Attard M; Reelfs O; Gusterson B; Bell AK; Heath V; Tavassoli M; Farrell PJ; Smith P; Lu X; Crook T
    Cancer Cell; 2003 Apr; 3(4):387-402. PubMed ID: 12726864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism.
    Siddique M; Sabapathy K
    Oncogene; 2006 Jun; 25(25):3489-500. PubMed ID: 16462765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
    He Y; Fan SZ; Jiang YG
    Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
    Cattelani S; Ferrari-Amorotti G; Galavotti S; Defferrari R; Tanno B; Cialfi S; Vergalli J; Fragliasso V; Guerzoni C; Manzotti G; Soliera AR; Menin C; Bertorelle R; McDowell HP; Inserra A; Belli ML; Varesio L; Tweddle D; Tonini GP; Altavista P; Dominici C; Raschellà G; Calabretta B
    Neoplasia; 2012 Jul; 14(7):634-43. PubMed ID: 22904680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models.
    Phang BH; Sabapathy K
    Oncogene; 2007 May; 26(21):2964-74. PubMed ID: 17130838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function.
    Huqun ; Endo Y; Xin H; Takahashi M; Nukiwa T; Hagiwara K
    Cancer Sci; 2003 Aug; 94(8):718-24. PubMed ID: 12901798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
    Vikhanskaya F; D'Incalci M; Broggini M
    Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
    Thottassery JV; Westbrook L; Someya H; Parker WB
    Mol Cancer Ther; 2006 Feb; 5(2):400-10. PubMed ID: 16505115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.
    Sullivan A; Syed N; Gasco M; Bergamaschi D; Trigiante G; Attard M; Hiller L; Farrell PJ; Smith P; Lu X; Crook T
    Oncogene; 2004 Apr; 23(19):3328-37. PubMed ID: 15077186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.
    Liu J; Uematsu H; Tsuchida N; Ikeda MA
    Mol Cancer; 2011 Jul; 10():95. PubMed ID: 21801448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein.
    Ozeki C; Sawai Y; Shibata T; Kohno T; Okamoto K; Yokota J; Tashiro F; Tanuma S; Sakai R; Kawase T; Kitabayashi I; Taya Y; Ohki R
    J Biol Chem; 2011 May; 286(20):18251-60. PubMed ID: 21454683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA; Ito D; Deleo AB; Ferris RL
    Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.
    Loeb KR; Asgari MM; Hawes SE; Feng Q; Stern JE; Jiang M; Argenyi ZB; de Villiers EM; Kiviat NB
    PLoS One; 2012; 7(4):e34422. PubMed ID: 22545084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
    Di Como CJ; Gaiddon C; Prives C
    Mol Cell Biol; 1999 Feb; 19(2):1438-49. PubMed ID: 9891077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53.
    Hayashi S; Ozaki T; Yoshida K; Hosoda M; Todo S; Akiyama S; Nakagawara A
    Biochem Biophys Res Commun; 2006 Aug; 347(1):60-6. PubMed ID: 16815295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer.
    McGregor JM; Harwood CA; Brooks L; Fisher SA; Kelly DA; O'nions J; Young AR; Surentheran T; Breuer J; Millard TP; Lewis CM; Leigh IM; Storey A; Crook T
    J Invest Dermatol; 2002 Jul; 119(1):84-90. PubMed ID: 12164929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.